Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)
- Conditions
- Migraine
- Interventions
- Drug: oxygenotherapyDrug: placebo air aerosol
- Registration Number
- NCT04925414
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Brief Summary
Migraine is a common pathology, affecting around 12% of the general population, up to 25% in some cohorts, as well as a significant part of the reasons for emergency room visits.
Unlike cluster headaches, the use of high-flow oxygen therapy has not yet been validated in patients with migraine.
However, several aspects of its pathophysiology, still studied to this day, suggest that the use of normobaric oxygen could have beneficial effects on migraine attacks: tissue hypoxia, cerebrovascular dysfunction with vasodilation, inflammation, etc.
In addition, high-flow oxygen therapy has no significant side effects and almost no contraindication (mainly COPD and other chronic respiratory failure) Its use in the event of a migraine attack would thus allow less recourse to conventional analgesics (with significant side effects for some), a shorter stay in the emergency room, and therefore a benefit in terms of cost and relief for the patient.
In this context, the sponsor wish to carry out a multicenter prospective interventional, single-blind randomized placebo-controlled in parallel groups study.
- Detailed Description
Migraine is a common pathology, affecting around 12% of the general population, up to 25% in some cohorts, as well as a significant part of the reasons for emergency room visits.
Unlike cluster headaches, the use of high-flow oxygen therapy has not yet been validated in patients with migraine.
However, several aspects of its pathophysiology, still studied to this day, suggest that the use of normobaric oxygen could have beneficial effects on migraine attacks: tissue hypoxia, cerebrovascular dysfunction with vasodilation, inflammation, etc.
In addition, high-flow oxygen therapy has no significant side effects and almost no contraindication (mainly COPD and other chronic respiratory failure) Its use in the event of a migraine attack would thus allow less recourse to conventional analgesics (with significant side effects for some), a shorter stay in the emergency room, and therefore a benefit in terms of cost and relief for the patient.
In this context, the sponsor wish to carry out a multicenter prospective interventional, single-blind randomized placebo-controlled in parallel groups study.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 70
- 18 years old or more
- Affiliated to a french public health insurance
- ED admission for migraine evocative headache, regarding ICHD3 criterions
- written informed consent
- COPD or other chronic respiratory failure conditions
- Pregnant or breastfeeding women or women of childbearing potential not using any means of contraception. A pregnancy test will be performed for women of childbearing age. The results will be communicated to the patient by a doctor of her choice.
- Under legal protection
- Patients who have received treatment with triptan in the past 2 weeks
- Patients who have consumed NSAIDs in the hour before the doctor's examination
- State of migraine headache (crippling attack for more than 72 hours)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description oxygenotherapy oxygenotherapy - placebo air aerosol placebo air aerosol -
- Primary Outcome Measures
Name Time Method Pain evaluation 30 minutes after aerosol started Simple 0-10 pain verbal numerical rating scale (0 being the minimum : no pain, and 10 the maximum : worst pain imaginable by the subject)
- Secondary Outcome Measures
Name Time Method Associated symptoms resolution From aerosol start to 90 minutes after Associated symptoms (nausea, photophoby, neurological troubles ) resolution
Assess pain level From 30 minutes after aerosol start to 90 minutes after Simple 0-10 pain verbal numerical rating scale
Occurrence of side effects From aerosol start to ED exit assesed up to 6 hours, an average of 3 hours Evaluate the occurrence of side effects
Assessing time spent in emergencies From ED admission to exit or transfert assesed up to 6 hours, an average of 3 hours Patient stay in the ED duration
Rescue analgesics usage From ED admission to exit or transfert assesed up to 6 hours, an average of 3 hours The frequency of analgesics administration during patients stay
Trial Locations
- Locations (1)
CHU de Nice
🇫🇷Nice, France